We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rectangle Image
Product News

First Data To Show Protective Role of T Cell in SARS-CoV-2

Rectangle Image
Product News

First Data To Show Protective Role of T Cell in SARS-CoV-2

Oxford Immunotec Global PLC (Nasdaq: OXFD) (the “Company”), a high-growth diagnostics company, today announced the release of data from a prospective cohort study in keyworkers in the UK – a collaboration between the Company and Public Health England (PHE). The data demonstrates that SARS-CoV-2 reactive T cells may be sufficient to give protection from COVID-19 and that serology alone may underestimate those at lower risk of clinical SARS-CoV-2 infection.

The paper published on MedRxiv ‘SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers’, presents data generated as part of the EDSAB-HOME study which investigated both antibody (serology) and T cell responses in a cohort of police, fire and healthcare workers.

In the study, T cells tests were conducted at enrolment in almost 3,000 participants using the Company’s standardized research use only T-SPOT® Discovery SARS-CoV-2 assay. These individuals were then followed up for subsequent development of symptomatic, PCR confirmed SARS-CoV-2 infection. None of the participants with a high T cell response developed symptomatic SARS-CoV-2 infection in the follow-up period, whereas amongst those with low T cell responses there were 20 confirmed infections. Further follow-up is planned to allow for updated analyses as case numbers rise which may help yield additional insights into disease risk.

These, and additional results from the data, suggest that:

  • Serology alone may underestimate the working-age population at lower risk of clinical SARS-CoV-2 infection 
  • Individual level risk stratification may be possible using T cell assays
  • Numbers of individuals with high levels of SARS-CoV-2 responsive T cells declines with increasing age, specifically in the absence of antibodies (serology), and this may explain higher illness incidence and severity in this group
  • The T-SPOT Discovery SARS-CoV-2 test detected PCR confirmed SARS-CoV-2 infections that were not positive in antibody (serology) testing. 


Dr David Wyllie, Consultant Microbiologist at Public Health England and the lead author of the study, said “We conducted a prospective cohort study in almost three thousand volunteers working in hospitals, and in the fire and police services in England. Four months into the study, 20 participants with lower T cell responses had developed COVID-19, compared with none among individuals with higher T cell responses. This suggests individuals with higher numbers of T-cells recognizing SARS-CoV-2 may have some level of protection from COVID-19, although more research is required to confirm this.”

Oxford Immunotec CEO, Dr Peter Wrighton-Smith said, “Our T-SPOT technology platform is the only globally regulated ELISPOT platform currently available and we are pleased that we may be able to use it to support efforts to combat COVID-19. Our collaboration with Public Health England is a great example of the public and private sector working together. The successful outcomes of this study would not have been possible without the specialist skills and resource available within Public Health England” 

Reference: Wyllie D, Mulchandani R, Jones HE, et al. SARS-CoV-2 responsive T cell numbers are associated with protection from COVID-19: A prospective cohort study in keyworkers. MedRxiv. 2020. doi:10.1101/2020.11.02.20222778

 


Advertisement